S. Shepherd

发表

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer

D. Visscher, A. Chen, E. Swisher, 2022, Cancer Chemotherapy and Pharmacology.

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

P. Philip, A. Zhu, M. Borad, 2021, The lancet. Gastroenterology & hepatology.

Abstract P4-22-02: Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) withBRCA1orBRCA2mutations and metastatic breast cancer

A. Jager, M. Robson, M. Friedlander, 2017 .

Enzyme Encoding a Neuropeptide-Amidating , a PHM Protein DIMMED Directly Activates Basic Helix-Loop-Helix Drosophila The

P. Taghert, J. Trigg, O. Shafer, 2014 .

The Drosophila Basic Helix-Loop-Helix Protein DIMMED Directly Activates PHM, a Gene Encoding a Neuropeptide-Amidating Enzyme

P. Taghert, DongKook Park, J. Trigg, 2007, Molecular and Cellular Biology.

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.

P. Philip, G. Abou-Alfa, R. Kelley, 2021 .

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

J. Berlin, H. Lenz, J. Marshall, 2018, British Journal of Cancer.

Chromaffin-adrenocortical cell interactions: effects of chromaffin cell activation in adrenal cell cocultures.

S. Shepherd, M. A. Holzwarth, 2001, American journal of physiology. Cell physiology.

Frog chromaffin and Adrenocortical Cell Co‐Cultures: A Model for the Study of Medullary Control of Corticosteroidogenesis

S. Shepherd, M. A. Holzwarth, Matilde A. Holzwarth, 1998, Journal of neuroendocrinology.

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

W. Gradishar, J. Garber, A. Jager, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Chromaffin cell depolarization results in modulation of corticosteroidogenesis in co-culture.

S. Shepherd, M. A. Holzwarth, 1996, Endocrine research.

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale

J. Garber, Eric F. Johnson, M. Robson, 2016, Future oncology.

Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2- BRCA-associated locally advanced or metastatic breast cancer (BC).

H. Wildiers, M. Friedlander, V. Giranda, 2015, Journal of Clinical Oncology.

A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC).

A. Chen, H. Tawbi, V. Giranda, 2015 .

Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).

A. Chen, H. Tawbi, A. Tan, 2014 .

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

A. Oberg, D. Visscher, A. Jager, 2019, Gynecologic oncology.

A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

A. Chen, V. Giranda, P. Fracasso, 2015 .

Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer

V. Giranda, M. Carducci, M. Hussain, 2014, Investigational New Drugs.

A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)

V. Giranda, T. Tamura, H. Xiong, 2015, Cancer Chemotherapy and Pharmacology.

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

P. Ansell, J. Gietema, M. D. de Jonge, 2018, Investigational New Drugs.

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

P. Ansell, J. Gietema, Diane A van der Biessen, 2018, Investigational New Drugs.

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer

H. Linden, P. Porter, E. Swisher, 2016, Clinical Cancer Research.

Outcome of BRCA 1/2-mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V).

A. Chen, H. Tawbi, A. Tan, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)

A. Chen, H. Tawbi, V. Giranda, 2023, Breast Cancer Research and Treatment.

Exposure–response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients

H. Xiong, R. Menon, S. Stodtmann, 2019, Cancer Chemotherapy and Pharmacology.

A phase I study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies.

A. Chen, T. Owonikoko, S. Ramalingam, 2012 .

Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced triple-negative breast cancer (TNBC) and/or BRCA mutation-associated breast cancer.

H. Linden, P. Porter, E. Swisher, 2014 .

P3-16-05: A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer.

E. Winer, R. Gelman, J. Garber, 2011 .

Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer

H. Xiong, Silpa Nuthalapati, S. Shepherd, 2017, Cancer Chemotherapy and Pharmacology.

A phase I study of chronically dosed, single-agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer (BRCA-wt).

A. Chen, H. Tawbi, A. Tan, 2012 .

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.

J. Berlin, H. Lenz, V. Giranda, 2014 .